Comparative Pharmacology
Head-to-head clinical analysis: BECLOMETHASONE DIPROPIONATE versus PULMICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BECLOMETHASONE DIPROPIONATE versus PULMICORT.
BECLOMETHASONE DIPROPIONATE vs PULMICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through binding to glucocorticoid receptors, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
Glucocorticoid receptor agonist; inhibits inflammatory mediators, reduces airway edema and mucus secretion.
Inhalation: 40-320 mcg twice daily (DPI or pMDI); maximum 640 mcg/day. Intranasal: 1-2 sprays (42-84 mcg) per nostril twice daily. Topical: Apply 0.025% cream/ointment twice daily.
Inhalation: 200-800 mcg twice daily for maintenance; maximum 1600 mcg/day. Nebulization: 0.5-1 mg twice daily.
None Documented
None Documented
Clinical Note
moderateBeclomethasone dipropionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin."
Clinical Note
moderateBeclomethasone dipropionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin."
Clinical Note
moderateBeclomethasone dipropionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is 2.8-3.1 hours after inhalation, with a slower phase attributed to slow dissolution from lung tissue; clinical context: supports twice-daily dosing.
The terminal elimination half-life of budesonide is approximately 2.0 to 3.6 hours in adults, with a mean of about 2.8 hours. This short half-life is consistent with its rapid clearance and lack of significant accumulation with once- or twice-daily dosing.
Primarily fecal (via bile) as metabolites, ~60-70%; renal excretion accounts for <10% of unchanged drug.
Budesonide is primarily metabolized in the liver via CYP3A4 to inactive metabolites. Approximately 60% of the dose is excreted in urine as metabolites, and 40% in feces. Less than 10% of unchanged drug is excreted renally.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
Beclomethasone dipropionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trovafloxacin."